A roundup of news from Novo Holdings, Single Use Support, Johnson & Johnson and Proteologix. Highlights below.  

* Novo Acquires Majority Stake in Life Sciences Tool Provider Single Use Support 
* J&J To Acquire Proteologix for $850 M 

---

Novo Acquires Majority Stake in Life Sciences Tool Provider Single Use Support 
Novo Holdings, the parent company of Novo Nordisk, has acquired a 60% majority stake in Single Use Support, a Kufstein, Austria-based life-sciences tool provider specializing in fluid and cold-chain management of drug substances. The company provides products and services for the handling, liquid transfer, freezing and cold-chain shipping of advanced therapies and biologics in pharmaceutical production. In addition to its headquarters site in Kufstein, Austria, the company operates a site in Lexington, Massachusetts, and has approximately 200 employees globally.  

Source: Single Use Support 

---

J&J To Acquire Proteologix for $850 M 
Johnson & Johnson (J&J) has agreed to acquire Proteologix, a bio/pharmaceutical company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with potential for an additional milestone payment. 

Proteologix’s portfolio includes PX128, a bispecific antibody, ready to enter Phase I development for treating moderate-to-severe (eczema) and moderate-to-severe asthma, and PX130, a bispecific antibody in preclinical development for moderate-to- severe atopic dermatitis.  

The transaction is expected to close mid-year 2024, subject to antitrust clearance and other customary closing conditions. 

Source: Johnson & Johnson